Rubius Therapeutics has torn up its strategy. After reviewing human data on its lead candidates, the cell therapy biotech concluded investment in its two clinical prospects “is no longer justified,” ...

It’s the end of the road for Rubius Therapeutics, a biotech that previously wanted to develop cellular therapies for rare diseases, cancer and autoimmune diseases. After a last-ditch effort last year ...

Rubius Therapeutics announced a 75% reduction to its workforce Tuesday morning as part of a broader corporate restructuring initiative. The majority of the layoffs will focus on clinical development ...

Cell therapy is one of the big ideas in biotech. Entrepreneurs have become captivated by possibilities of engineering white blood cells so they can be re-infused into patients and fight cancer. One ...

SMITHFIELD, R.I. (WPRI) – The manufacturing facility vacated last fall by Alexion Pharmaceuticals is getting a new owner. Rubius Therapeutics, a Cambridge-based biotech firm that just made a ...

Rubius Therapeutics went public in 2018 at a $2 billion valuation — the largest biotech stock market debut at that time. On Wednesday, the company — battered down to a market value of $15 million — ...